The global Vaccine Market was valued at over USD 32.5 billion in 2015 and is expected to reach over USD 77.5 billion by 2024, at a CAGR of 10.3%. A lot of vaccines technologies that could assist in improved safety, effectiveness and deliverance are in progress, such as needle liberated administration, escalating the magnitude and long lasting existence of defensive immune responses provoked by vaccines at the same time as plummeting the dose, and enhanced vaccine stabilization.
The worldwide industry for vaccines is expected to nurture, owing to technical advancements in admiration to the expansion of new vaccines towards cancers, rising infectious diseases and allergies. The industry will acknowledge constant progress in delivery methodologies, vaccine design, and manufacturing in huge scale process. The industry is expected to witness a drift towards the expansion of customized vaccines. In addition, to which the requirement for cost effective and safe drugs for the cure of HIV infection, many cancers which could be dealt by therapeutic vaccines, will outstandingly fuel the market growth over the forecast period. Inside the healthcare market, the vaccine market was originally considered a small profit venture but is presently professed with transformed interest among market circles owing to its huge demand in regard to rising infectious diseases.
In addition, an enhanced and considerate understanding of the immune system has cemented new prospects for making new therapeutic and preventive vaccines. Rapid advancements in consideration of the immune system and wish of medical society to engineer both therapeutic and preventive vaccines for a wide-ranging field of diseases are expected to fuel the changes in the managed care industry and medicine industry which in return is expected to fuel the growth of the market. The expansion of worldwide Vaccine industry is partially fuelled by technical breakthroughs such as genome sequencing of contagious pathogens, sophisticated understanding of the immune system and its instrumentation of reaction, chased by a noteworthy influx of money from civic funding bodies, commercial organizations and private charity. Safety, the manifestation of adequately high efficiency and lack in a requirement of a reliable evaluation and development pathway are the main obstructing blocks for making new vaccines.
Additionally, discovering novel and more efficient ways of healing rising public health threats, there is substantial focus on recovering access to immunization for people in developed and developing countries. There is an imbalance in demand to create effective vaccines in opposition to a number of lethal infectious diseases such as malaria, hepatitis C and AIDS. Even though, vaccines for Infectious diseases such as influenza and TB exist, but are only partly effectual and this sector demands significant upgrading to react for the actual public health needs. This imbalance is expected to pose the challenge for this market over the forecast period.
On the basis of technology class, the market can be segregated into Conjugate Vaccines, Toxoid Vaccines, Sub-Unit Vaccines, Recombinant Vector Vaccines, Live/Attenuated Vaccines, DNA Vaccines, Synthetic Vaccines and Dentritic Vaccines. On the basis of the type, the market can be segregated into Therapeutic and Preventive. On the basis of end users, the market can be segmented into Adult and Paediatric. On the basis of disease indication, the market can be segregated into Infectious Diseases, Cardiovascular Diseases, Allergies, Cancer and Others such as Diabetes. On the basis of a geographical region, the market can be segregated into North America, Asia Pacific, Europe and Rest of the world. Asia Pacific is expected to grow rapidly over the forecast period owing to increasing demands of a vaccine in the countries like India and China coupled with rising awareness about the usage of vaccines. North America is expected to capture maximum revenue over the forecast period owing to great awareness of vaccine and increasing regulation by government to strengthen the vaccination process. North America is followed by Europe.
Some of the key players in the market are Sanofi, Glaxo SmithKline PLC, Merck & CO., INC., Novartis AG, Aduro biotech, ImmunoCellular Therapeutics Ltd, Antigen Express, INC, Agenus Inc, Galena Biopharma Inc., Dynavax Technologies Corp., and Inovio Pharmaceuticals. The companies are focused on initiating the DNA-supported vaccines to stop and cure cancer and infectious diseases. The market is less fragmented and there is the lack of standardization which is expected to pose the challenge for the players over the forecast period. As the number of contagious diseases is increasing, the key companies playing in this area try their best to incorporate latest innovations in their vaccines so that they can have more effective vaccines. This market is expected to be innovation driven over the forecast period.
Global Vaccines Market By Type (Revenue, USD Million, 2013 - 2024)
• Inactivated vaccines
• DNA vaccines
• Attenuated vaccines
• Subunit vaccines
• Conjugate vaccines
• Toxoid vaccines
Global Vaccines Market By Application (Revenue, USD Million, 2013 - 2024)
• Infectious diseases
Vaccines Market By Region (Revenue, USD Million, 2013 - 2024)
• North America
• Asia Pacific
• Latin America
• South Africa
Research Support Specialist, USA